Cartesian Therapeutics 4/30/2026 Earnings Report

Cartesian Therapeutics EPS Results

• Actual EPS: -$1.46
• Consensus EPS: -$0.84
• Beat/Miss: Missed by -$0.62
• One Year Ago EPS: N/A

Cartesian Therapeutics Revenue Results

• Actual Revenue: $0.08 million
• Expected Revenue: $0.22 million
• Beat/Miss: Missed by -$142.00 thousand
• YoY Revenue Growth: N/A

Cartesian Therapeutics Announcement Details

• Date: 4/30/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Cartesian Therapeutics (NASDAQ:RNAC), trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations. By combining nucleoside‐modified mRNA with bespoke LNP carriers, the company seeks to enhance cellular uptake and reduce immunogenicity, positioning its pipeline candidates for both systemic and localized therapeutic interventions. Cartesian’s preclinical programs include immuno-modulatory candidates intended to boost anti-tumor immunity, as well as mRNA constructs designed to reestablish immune tolerance in autoimmune disease models. The firm has also entered strategic collaborations with academic institutions and contract research organizations to support IND-enabling studies and expand its translational research capabilities.

Founded as a spin-out from leading academic research laboratories, Cartesian Therapeutics completed its initial public offering in 2021. Headquartered in New Jersey, the company engages with a broad network of scientific and clinical partners across North America and Europe. Cartesian’s leadership team includes experienced executives drawn from both biotech start-ups and larger pharmaceutical organizations, underscoring its commitment to advancing mRNA science from bench to bedside. As Cartesian progresses toward clinical milestones, it aims to establish itself as a key innovator in the rapidly evolving field of RNA therapeutics.